Novel Immunotherapeutics to target Gram-negative bacterial infections

Wed24  Feb10:55am(20 mins)
Conference Room 2
 Mike Westby


Agents that have the ability to modulate the immune system, have proved useful in many therapeutics areas. Centauri has developed an immunotherapeutic platform (Alphamers) that redirects pre-existing natural antibodies to target specific diseases.
Alphamers comprise a targeting domain that binds to specifically to the bacteria, an antibody-recruiting effector domain that recruits pre-existing natural anti-Gal antibodies, and proprietary linker technology. The effector domain is a trisaccharide epitope, galactose-alpha-1,3-galactose-beta-1,4-N-acetyl glucosamine (alpha-Gal). Alpha-Gal is a natural glycan component of tissue in all mammalian species except for humans, apes, and old-world monkeys. Constant exposure of humans to alpha-Gal epitopes in the gut leads to production of anti-Gal antibodies, which are amongst the most abundant natural immunoglobulins detected in serum. The Alphamer re-directs these naturally occurring effector antibodies to target bacteria for immune-mediated destruction.
s lead program (CTL-ABX01) targets drug-sensitive and Multi-Drug Resistant (MDR) Gram-negative bacteria, including clinically relevant strains of Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. The targeting domain of the Alphamer of the ABX01 program has also a direct antibacterial effect in combination with its immunomodulator function. As such, the Alphamer serves as a method to combine the power of the immune system with direct antibacterial action in one drug.

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021